On November 5th, the FDA approved the use of Genvoya, a new and safer single tablet HIV medication, manufactured by Gilead Sciences. This is exciting news because Genvoya is the first single tablet regimen to contain Tenofovira alafenamide, commonly referred as “TAF”.
TAF is an improved and safer version of Tenofovir, currently found in the single tablet regimens of Stribild, Atripla, and Complera. The components of Genvoya are almost identical to that of Stribild, except TAF has replaced Tenofovir. The substitution of TAF in place of Tenofovir is exciting for several reasons. First, it enters the cells in the body more efficiently!
Second, it requires a lower dose and 91 % less of this medication ends up in the blood stream! Finally, since less of this medication will end up in the blood stream, it has been shown to be less toxic to bones and the kidneys! Whether you are about start medication for the first time or interested in switching/updating your current regimen, we encourage you to have a discussion with your provider to determine if Genvoya is the right choice for you.